These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23024989)

  • 1. Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
    Doss S; Robertson J; Adam J
    Lancet Oncol; 2012 Aug; 13(8):766-7. PubMed ID: 23024989
    [No Abstract]   [Full Text] [Related]  

  • 2. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
    Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
    Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
    Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hints of future progress for HER-2 breast cancer.
    Twombly R
    J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
    [No Abstract]   [Full Text] [Related]  

  • 10. Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Mehta A; Tripathy D
    Breast; 2014 Feb; 23(1):2-9. PubMed ID: 24176518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
    Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
    Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
    Diaby V; Alqhtani H; van Boemmel-Wegmann S; Wang CY; Ali AA; Balkrishnan R; Ko Y; Palacio S; de Lima Lopes G
    Breast; 2020 Feb; 49():141-148. PubMed ID: 31805500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
    Candon D; Healy J; Crown J
    Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
    Valachis A; Nearchou A; Lind P; Mauri D
    Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
    Wu Y; Amonkar MM; Sherrill BH; O'Shaughnessy J; Ellis C; Baselga J; Blackwell KL; Burstein HJ
    Ann Oncol; 2011 Dec; 22(12):2582-2590. PubMed ID: 21406472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
    Guarneri V
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1549-57. PubMed ID: 19895239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib: a sword with two edges.
    Kopper L
    Pathol Oncol Res; 2008 Mar; 14(1):1-8. PubMed ID: 18409020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.